KPV Peptide Guide: FDA Status and Compliance Position
Three amino acids. Lysine, proline, valine. That is the whole molecule, short enough to write on the back of a business card, and it is the smallest item most clinics will ever see raised in the tissue repair category. It also carries less human evidence than almost anything else that gets mentioned alongside it.
Phoenix Meds Inc. is a sourcing coordinator and compliance specialist working between licensed clinics and licensed pharmacies in the United States. We are a non-dispensing entity: we do not manufacture, compound, prescribe, or dispense pharmaceuticals. We published this because clinics keep asking us the same question about it, and most of the answers circulating right now are wrong in the same direction. Our broader work on the medical supply chain for clinics covers how sourcing decisions are normally documented.
What follows is a regulatory and evidence summary. It is not clinical guidance, it is not a recommendation, and it is not an offer to source KPV for any purpose.
What KPV is
KPV did not appear out of nowhere. It is the tail end of a larger hormone, alpha-melanocyte-stimulating hormone, usually shortened to alpha-MSH. In the literature it is written as alpha-MSH(11–13), meaning the eleventh, twelfth, and thirteenth residues of that hormone. Researchers have studied the parent hormone in connection with inflammation regulation for several decades.
KPV draws separate attention because this three-residue tail appears to retain some of the anti-inflammatory activity associated with the parent while leaving behind the pigmentation effects for which alpha-MSH is better known. Those pigmentation effects trace to a different region of the sequence, further up the chain, which KPV does not contain. Laboratory work has examined KPV in models of intestinal inflammation and in corneal and skin healing, which is why it comes up in inflammatory and wound contexts rather than structural repair.
The underlying concept is ordinary science. Take a hormone with a useful property, identify the smallest fragment that appears to carry it, and study the fragment. What has not followed is the human research that would normally come next.
How much human evidence exists
This deserves numbers rather than adjectives.
A ClinicalTrials.gov search for KPV, run on 20 August 2026, returns nothing at all. No completed trials, none recruiting, none withdrawn. The published literature is modest: roughly two dozen papers examine the tripeptide directly, and a broader search capturing related melanocortin work brings the total to around sixty, published from about 2000 onward. Almost all of it is preclinical, and a substantial share of the recent output concerns delivery-system engineering rather than clinical investigation.
The FDA reached the same conclusion in its own file. The agency’s entry for KPV, which now sits in the withdrawn-nomination table on its Category 2 bulk substances page, reads:
FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration. FDA lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans.
That sentence is easy to misread in either direction. The agency has not found KPV dangerous, and it has not found KPV safe. It is recording that the evidence needed to answer the question has never been produced. The practical consequence is narrow and specific: it sets a hard ceiling on what anyone can honestly claim about this molecule.
The agency said the same thing again in its July 2026 briefing document, noting that it did not identify clinical studies in humans assessing the pharmacokinetics or pharmacodynamics of KPV free base or KPV acetate via any route.
Where the FDA stands
Two developments in 2026 point in different directions, and both matter.
In April, the FDA removed KPV from the Category 2 list, the file of bulk substances that may present significant safety risks in compounding. Eleven other peptides came off at the same time, among them BPC-157, TB-500, MOTS-c, Epitalon, and Semax. The stated reason was procedural rather than scientific: the nominators had withdrawn their nominations, so the substances moved into the agency’s withdrawn-nomination table.
Removal from Category 2 is not clearance, and it is the single most misreported fact in this category. These substances did not move to Category 1. They remain off both bulks lists and outside the agency’s enforcement discretion policy. Nothing about their legal status improved in April.
On 23 and 24 July, the Pharmacy Compounding Advisory Committee met to consider seven peptides for the 503A Bulks List. FDA scientists recommended against every one of them, citing insufficient safety, effectiveness, and characterization data. The committee disagreed on six. KPV was recommended for inclusion by a vote of eight to six, with one abstention, for wound healing and inflammatory conditions. Emideltide was the only peptide the committee declined to recommend.
Speakers during the public comment period proposed guardrails around any future listing, including controls on active ingredient sourcing, mandatory adverse-event reporting, and limits on permitted formulations. Those proposals were not adopted as conditions of the vote, and it is worth understanding why. Under section 503A the FDA cannot regulate the practice of pharmacy through the bulks listing process. It cannot require state-licensed pharmacies to report adverse events, register with the agency, submit to surveillance inspections, or source active ingredients from specified suppliers. A listing decision is a decision about one substance, not a framework around it.
None of this changes what is lawful today. An advisory committee issues a non-binding recommendation. The FDA may accept it, decline it, request additional data, or take more time. Adding a substance to the 503A Bulks List requires notice-and-comment rulemaking, and observers expect that process to run into 2027 or 2028. A further PCAC meeting is scheduled for February 2027 to take up additional peptides. Until rulemaking concludes, nothing has changed for a pharmacy or a prescriber.
What “not on either list” means in practice
KPV appears on neither bulks list. The 503A list does not include it, and the 503B list, which outsourcing facilities work from, currently contains five substances, none of them peptides. KPV is not a component of an FDA-approved drug product and has no applicable USP or NF monograph.
Compounding is a legitimate and heavily used pathway, and we have written elsewhere about how compounded preparations are regulated. The rules are specific. Section 503A permits compounding from a bulk drug substance only where that substance has an applicable USP or NF monograph, is a component of an FDA-approved drug, or appears on the 503A Bulks List. KPV satisfies none of the three. Stated directly: there is at present no lawful route for a United States pharmacy or outsourcing facility to compound KPV into a human drug product.
That single fact resolves most of the questions clinics bring to us. You are not choosing between a compliant 503A source and a compliant 503B source, because neither exists for this substance today. If a supplier tells you otherwise, the correct response is to ask which of the three statutory conditions they believe KPV satisfies, and to get the answer in writing. There is no fourth answer. The same principle drives our general guidance on choosing a reliable medical injectable supplier: the first question is always statutory status, not price or purity.
The research-use-only channel
Most KPV in circulation moves as research-grade material, labeled “for research use only, not for human consumption.” That labeling carries legal weight and is not a technicality or a formality.
Purchasing research-grade material and administering it to a patient is the most common compliance failure in this category and the one most likely to draw an FDA warning letter. The label is not a disclaimer the seller added for their own protection while everyone understands the real use. It is a statement about what the material is authorized for, and buying it with clinical intent does not change what it is.
The same analysis applies to blends. Where KPV appears as one component of a multi-peptide combination, the regulatory position of that combination is no stronger than the position of its weakest component. Combining an unapproved bulk substance with other unapproved bulk substances does not produce a compliant product.
KPV at a glance
| Consideration | Where KPV stands |
|---|---|
| Size | Three amino acids: lysine, proline, valine |
| Origin | C-terminal fragment of alpha-MSH, residues 11–13 |
| Research context | Preclinical models of intestinal inflammation and wound healing |
| Registered trials | None found on ClinicalTrials.gov, 20 August 2026 |
| Published literature | Roughly two dozen directly relevant papers, almost all preclinical |
| FDA approval | None |
| Category 2 status | Removed April 2026 after the nomination was withdrawn; removal does not confer eligibility and does not place KPV in Category 1 |
| 503A Bulks List | Not included. Advisory committee recommended inclusion 8–6, one abstention, July 2026; rulemaking has not occurred |
| 503B Bulks List | Not included |
| USP or NF monograph | None applicable |
| FDA safety position | No human exposure data identified via any route of administration |
| Lawful compounding route today | None |
How KPV compares with better-studied peptides
It is worth seeing where KPV sits relative to other molecules that come up in the same conversations, because the gap is wider than most marketing suggests.
Some peptides in this category carry a real published record, including human work. Our summary of the clinical evidence behind GHK-Cu is an example of a molecule with decades of study behind it, and our clinician’s guide to growth hormone secretagogue peptides covers a class where several members have been through human trials.
Evidence and legal status are separate questions, and it is a mistake to collapse them. A molecule can have substantial published research and still lack a lawful compounding route, and several peptides removed from Category 2 in April 2026 fall exactly there. KPV is unusual in that it currently sits on the weaker side of both: minimal human evidence and no statutory pathway. Treat the two tests independently whenever you assess anything in this category.
What belongs in a clinic’s file today
Clinics sometimes ask us what documentation they should be collecting on KPV. Given the position above, the honest answer is that the file is not about the substance. It is about the decision.
If KPV has been proposed to your practice by a supplier, a consultant, or a colleague, the record worth keeping is the one showing you checked. That means a dated note of the regulatory position at the time it was raised, a copy of any written legal basis the offering party provided, and a record of the decision you reached. This is ordinary diligence, and it is the difference between a practice that looked and a practice that did not. The same record-keeping logic applies across every wholesale sourcing decision a clinic makes.
What does not belong in the file is a certificate of analysis for a substance with no lawful clinical route. A certificate confirms identity and purity. It does not confer eligibility, and a well-documented file on an ineligible substance does not improve the position. Documentation supports a compliant decision; it does not substitute for one.
How to talk about KPV
Truthful representation is a legal obligation, not a matter of house style, and it applies to conversation as much as to marketing copy.
Anyone in your practice can accurately say that KPV is a small fragment of a hormone associated with inflammation regulation in laboratory research, that the published work is largely preclinical, that it holds no FDA approval, and that there is currently no lawful route to compound it for human use. What no one should do is imply proven outcomes, established safety, pending approval, or a compounding pathway that does not exist. “The FDA is about to approve it” is not an accurate description of an advisory committee recommendation, and it is the sentence most likely to create a problem.
Re-check the position before treating anything here as current. This category moved twice in 2026 alone.
What would have to change
For KPV to become lawfully compoundable under section 503A, the FDA would need to issue a proposed rule adding it to the 503A Bulks List, take public comment, and issue a final rule. The agency is not obliged to follow the committee’s recommendation, and its own scientists recommended against it. Watch the Federal Register rather than the trade press, and treat the publication of a final rule, not a vote and not a headline, as the moment the position changes.
Frequently asked questions
What is KPV, and why does it come up?
KPV is a tripeptide composed of lysine, proline, and valine, corresponding to residues 11 to 13 of the hormone alpha-MSH. Laboratory research has associated it with anti-inflammatory activity, which is why it appears in inflammatory and wound-related discussions among peptides marketed to clinics.
Is KPV FDA approved?
No. KPV holds no FDA approval. It remained on the FDA’s Category 2 list until April 2026, when it was removed because the nomination behind it had been withdrawn. An advisory committee recommended it for the 503A Bulks List in July 2026 by a vote of eight to six with one abstention, but a recommendation is not an approval, and rulemaking has not taken place.
Can a pharmacy lawfully compound KPV at present?
No. KPV is on neither the 503A Bulks List nor the 503B Bulks List, is not a component of an approved drug, and has no applicable USP or NF monograph. Those are the three statutory routes under section 503A, and KPV meets none of them. Any supplier suggesting otherwise should be asked to identify which condition they believe is satisfied, in writing.
Did removal from the Category 2 list make KPV legal?
No. The removal was procedural, prompted by nominators withdrawing their nominations. KPV moved to a withdrawn-nomination table, not to Category 1, and it remains outside the FDA’s enforcement discretion policy. Its legal status did not improve.
How much human research exists on KPV?
Very little. ClinicalTrials.gov lists no registered trials as of 20 August 2026. The directly relevant published literature amounts to roughly two dozen papers, nearly all preclinical. The FDA has stated that it identified no human exposure data for KPV via any route of administration.
What is Phoenix Meds Inc.’s role?
We are a non-dispensing sourcing coordinator and compliance specialist working between licensed clinics and licensed pharmacies in the United States. We do not manufacture, compound, prescribe, or dispense pharmaceuticals, and we do not provide medical or legal advice. Clinical decisions rest with the prescribing provider, and questions of statutory status should be confirmed with the licensed pharmacy involved and with your own counsel.
How should staff describe KPV if a patient raises it?
Accurately and conservatively. Explain what the molecule is, state that research remains largely preclinical, state that it holds no FDA approval and no lawful compounding route, and direct every clinical question to the prescribing provider. Avoid any language implying proven results or imminent approval.
Disclaimer
This article is for educational and regulatory tracking purposes. It is not medical advice, not legal advice, not a treatment recommendation, and not a claim that KPV is safe, effective, or appropriate for any use. Phoenix Meds Inc. is a non-dispensing sourcing coordinator and compliance specialist. We do not manufacture, compound, prescribe, or dispense pharmaceuticals.
KPV holds no FDA approval, appears on neither the 503A nor the 503B bulks list, has no applicable USP or NF monograph, and the FDA has stated that it identified no human exposure data for it via any route of administration. Regulatory status in this category is actively changing. Verify current FDA and state rules before acting, keep patient communication and marketing truthful, rely on qualified prescribers for clinical decisions, and source only through properly licensed pharmacies and wholesalers.